




Curriculum Vitae

Personal Information	
Title	Professor
Name	Yao/He
Degree	MD/PhD
Country	China
Affiliation	The First Affiliated Hospital of ZhongShan University, Guangzhou, China
	
Educational Background	
1985-1991: Undergraduate student, Sun Yat-sen University of Medical Sciences, MBBS awarded 1995-2000: Postgraduate student, Sun Yat-sen University of Medical Sciences, Ph.D. awarded 2005-2008: Postdoctoral fellow, Cedars-Sinai Medical Center, USA 2012.7-2012.9: Visiting scientist, The University of Texas Southwestern Medical Center, USA	
Professional Experience	
1991-1998: Resident, The First Affiliated Hospital, Sun Yat-sen University of Medical Sciences 1998-2002: Attending physician and lecturer, Division of Gastroenterology, The First Affiliated Hospital, ZhongShan University 2002-2009: Associate professor, Division of Gastroenterology, The First Affiliated Hospital, ZhongShan University 2010-to date: Professor, Division of Gastroenterology, The First Affiliated Hospital, ZhongShan University	
Professional Organizations	
Vice group leader, IBD group, Digestive Diseases Branch of Chinese Medical Association, China Vice-president, Endoscopy Branch of Guangdong Medical Doctor Association, China Vice-president, Digestive Diseases Branch of Guangdong pharmaceutical association, China Vice-president, Endoscopy Branch of Guangdong association of hepatology, China Vice group leader, Nutrition support group, Digestive Disease Branch of Guangdong Medical Association, China	
Main Scientific Publications	
(1) Mucosal Healing and Quality of Life in Therapeutic Goals of Ulcerative Colitis: Occurrence and Related Factors of Functional Bowel Disorders. <i>Therap Adv Gastroenterol</i> 2022;17562848221092597.doi: 10.1177/17562848221092597 (2) Multi-omics Analysis of Western-style Diet Increased Susceptibility to Experimental Inflammatory Bowel Disease. <i>J Inflamm Res</i> 2022 Apr 21;15:2523-2537 (3) Thalidomide induces clinical remission and mucosal healing in adults with active Crohn's disease: a prospective open-label study. CYP2C19 polymorphism has no correlation with the efficacy and safety of thalidomide for the treatment of immune-related bowel disease. <i>J Dig Dis</i> . 2020 Feb;21(2):98-103. (4) Epstein-Barr virus status on clinicopathologic characteristics and clinical outcomes in ulcerative colitis: a	



- study on high incidence area of the viral infection. *Therapeutic Advances in Gastroenterology* 2020
- (5) Development and validation of a novel diagnostic nomogram to differentiate between Intestinal tuberculosis and Crohn's Disease: A 6-year prospective multi-center study. *Am J Gastroenterol* 2019 Mar;114(3):490-499